Akathisia (Primary & Secondary)
Akathisia: The Unseen Agony
Understanding Primary and Secondary Form
By David Powers, Ph.D.
Abstract
This article differentiates between primary akathisia, driven by acute neurochemical destabilization, and a secondary, conditioned form maintained by autonomic fear conditioning and limbic sensitization. Drawing on research in psychopharmacology, trauma science, interoceptive conditioning, and inhibitory learning models, this framework clarifies mechanism, prognosis, and treatment implications. Distinguishing between pharmacological and conditioned drivers of restlessness restores clinical nuance and provides a pathway toward recovery grounded in neuroplasticity rather than catastrophic interpretation.
Disclaimer:
Akathisia is a serious and distressing topic. This article is intended to provide clarity and reduce fear-based distortions, not to alarm. If you are currently in an acute withdrawal wave or highly sensitized state, consider reading this at a later time. For most individuals in long-term recovery, this discussion is educational rather than directly applicable.
Akathisia is one of the most distressing syndromes encountered in psychiatric medication withdrawal and medication reactions. It is characterized by profound inner restlessness accompanied by a compelling need to move. Individuals often describe it as feeling unable to inhabit their own body, a sensation of internal agitation so intense that stillness becomes intolerable. Externally, this may manifest as pacing, rocking, shifting weight, or repetitive movements. Internally, it can feel like psychological torment.
Because of its intensity, akathisia has become one of the most feared complications discussed in benzodiazepine and psychiatric withdrawal communities. Yet the way it is described online often collapses distinct biological phenomena into a single catastrophic narrative. There is, in fact, important nuance.
Clinically and conceptually, it is useful to distinguish between what can be called primary akathisia and secondary akathisia. While these are not formal DSM subtypes, the distinction clarifies mechanism, prognosis, and treatment approach.
Understanding this difference reduces fear and restores perspective.
What Is Primary Akathisia?
Primary akathisia refers to a direct pharmacological reaction resulting from acute neurochemical destabilization. It most commonly occurs shortly after initiating, increasing, decreasing, or discontinuing certain centrally acting medications. Antipsychotics are the most well-documented cause, but antidepressants, benzodiazepines, and other psychoactive agents have also been implicated.
Mechanistically, primary akathisia is associated with abrupt alterations in dopaminergic signaling, particularly within the nigrostriatal and mesocortical pathways. Antipsychotic-induced akathisia, for example, is thought to arise from dopamine D2 receptor blockade in motor and limbic circuits. In withdrawal states, rapid shifts in GABAergic inhibition and glutamatergic excitation may similarly destabilize regulatory networks.
Clinically, primary akathisia tends to emerge within hours to days of a medication change. Its onset is often abrupt and its intensity severe. Individuals may report overwhelming internal agitation, visible motor restlessness, and, in extreme cases, profound psychological distress. The condition is recognized in psychiatry as a medical emergency when severe, particularly because of its association with increased impulsivity and suicidality.
The Barnes Akathisia Rating Scale (BARS) was developed to assess this presentation, focusing on both objective motor signs and subjective inner restlessness. In true primary akathisia, both components are typically present and proportionate to recent pharmacological change.
Importantly, primary akathisia is not a moral failure, a psychological weakness, or a personality trait. It is a drug-induced neurobiological reaction.
It is also usually time-limited when properly addressed, meaning it will calm down.
How Long Does Primary Akathisia Typically Last?
There is no universal timeline, but clinical literature provides some general patterns.
Acute primary akathisia most often emerges within hours to days after starting, increasing, decreasing, or abruptly discontinuing a centrally acting medication. Antipsychotics remain the most well-documented cause, though antidepressants and benzodiazepine withdrawal have also been implicated in some cases. The onset is typically closely tied to a clear pharmacological event.
In many individuals, symptoms improve within days to weeks once the medication is adjusted, reinstated, tapered more gradually, or metabolized. In discontinuation-related cases, resolution often parallels neurochemical stabilization. The nervous system recalibrates, and the intense motor restlessness gradually subsides.
There is also a recognized form sometimes referred to as tardive or protracted akathisia. This presentation may emerge weeks to months after medication exposure or discontinuation and can persist longer than acute akathisia. Case reports document symptoms lasting several months, and more rarely, longer durations. However, even in these presentations, functional improvement over time is common. Persistent symptoms do not imply irreversible structural injury. They reflect prolonged neuroadaptation within dopaminergic and regulatory circuits.
Importantly, even in documented cases of protracted akathisia, the condition is understood as a disorder of neurochemical regulation, not neuronal death.
When Symptoms Persist:
Understanding Conditioned Autonomic Reactivation
There is another phenomenon that is frequently mislabeled as chronic or “permanent” akathisia but is better understood through the lens of conditioned autonomic arousal.
After an episode of true primary akathisia, particularly one that was severe or traumatic, the nervous system may become sensitized not only to medication changes but to the memory of the experience itself. The original pharmacological destabilization may have resolved, yet the body remains vigilant.
In this state, internal sensations such as mild restlessness, anxiety, or activation can trigger a powerful alarm response. The individual may begin to fear stillness, silence, or bodily sensations associated with the prior episode. Movement becomes both a symptom and a coping strategy.
The body learns that pacing reduces distress, and this behavioral loop reinforces the state. This is critical to know.
This presentation can include:
persistent internal agitation
difficulty tolerating stillness
compulsive movement or pacing rituals
heightened fear of recurrence
catastrophic interpretation of normal fluctuations
misinterpreting adrenaline surges for akathisia
The suffering is real. The physiology is real. But the mechanism is different.
Rather than ongoing pharmacological toxicity, this pattern aligns with what trauma researchers describe as conditioned autonomic states. In post-traumatic stress, the nervous system can reactivate survival responses long after the original danger has passed. The brain does not distinguish between current threat and remembered threat when sensory cues overlap.
Similarly, individuals who have experienced severe akathisia may develop interoceptive fear conditioning. The body becomes hyper-alert to internal sensations, and minor fluctuations are interpreted as the return of catastrophe.
This creates a self-perpetuating loop: fear increases arousal = arousal increases restlessness = restlessness confirms fear.
Some patients describe this as “phantom akathisia.” Not imaginary, but maintained by conditioned alarm circuitry rather than active drug injury.
This distinction matters profoundly.
If ongoing symptoms are driven primarily by conditioned limbic activation rather than continuing neurochemical influences, the path forward shifts. The focus moves from searching for biochemical antidotes to retraining the nervous system’s interpretation of internal signals.
And unlike structural injury, conditioned autonomic responses are plastic. They can be reshaped through gradual exposure, fear retraining, behavioral stabilization, and restoration of safety signals. This is a huge part of what my recovery program focuses on, and why I created a Four-Stage system that attempts to meet a dysregulated, sensitized limbic system where it currently is.
Differentiating Primary vs. Secondary Akathisia
Differentiating primary from secondary akathisia can be helpful, though it can also be challenging. Perhaps the best evidence is time itself. Most people who experience primary akathisia do so upon being cold-turkeyed or rapidly tapered off their medications, usually after many years of use, and at higher doses of the drug. In this case, the symptom usually appears quickly and will fade within weeks or months.
However, that's not always the case. Most people cold-turkeyed or rapidly tapered will not go on to experience akathisia, while a smaller subset of users will experience this symptom even while doing a gradual taper. Again, I must highlight the complexity in differentiating akathisia from acute withdrawal symptoms like restlessness, anxiety, protracted withdrawal, and adrenaline surges, which are most often mistaken.
Below are some points that might be helpful in better identifying the two.
Primary Akathisia
Origin: Caused directly by drug toxicity, imbalance, or sudden withdrawal
Timeline: Often begins immediately or within days of med changes
Physical Signs: Classic pacing, fidgeting, inner restlessness, rocking, with a chemical feel
Response to Medication: May partially or fully improve with reinstatement, beta-blockers (e.g., propranolol), mirtazapine, or slow taper
Resolution: Often clears once the brain re-stabilizes chemically
Secondary Akathisia (Trauma-Driven / Conditioned)
Origin: Formed through limbic fear conditioning and nervous system dysregulation from prolonged suffering or trauma during withdrawal
Timeline: May persist long after withdrawal is over, even months or a year out
Physical Signs: Feels similar, pacing, agitation, terror, but often comes in waves or flares with stress, and may not respond to medication
Response to Treatment: Improves more with somatic therapy, exposure work, mindfulness, limbic retraining, polyvagal interventions, and neuroplasticity tools
Resolution: As neuroplasticity strengthens and the limbic system unlearns the fear loop, symptoms reduce and often disappear.
The Risk of Over-Medicalizing Everything
When akathisia is framed exclusively as irreversible drug injury, the message becomes one of passivity. We are told by the benzo community to simply wait, endure, and hope for time alone to resolve it.
While medication-induced reactions are real and sometimes severe, reducing every persistent presentation to powerful neuroadaptation changes can inadvertently strip individuals of agency. If the only explanation is permanent injury, then there is no meaningful behavioral pathway forward.
That narrative can be psychologically paralyzing.
In contrast, when persistent restlessness is understood through the lens of conditioned autonomic activation, the clinical picture changes. The question shifts from “What is permanently broken?” to “What has been learned, and how can it be unlearned?”
This distinction matters because learned alarm responses can be modified. Just as continuously reinforcing false narratives of brain-damage can keep the amygdala in survival mode, and symptoms can persist. This creates a kind of confirmation bias loop.
When symptoms are maintained by fear-based reinforcement loops rather than ongoing pharmacological insult, several evidence-based approaches become relevant:
Gradual exposure to stillness, allowing the nervous system to relearn that immobility is not dangerous
Interrupting rumination and catastrophic interpretation, reducing limbic amplification
Decoupling sensation from threat, particularly the pairing of “internal activation = imminent catastrophe”
Somatic regulation practices, including paced breathing, grounding, and vagal tone exercises
Restoring rhythm and predictability, which stabilize autonomic fluctuation
These interventions are not attempts to dismiss suffering. They are attempts to target mechanism.
If the system is caught in high-conditioned alert, it can be gently rewired. The presence of persistent distress does not automatically indicate structural injury, but it may indicate entrenched autonomic learning.
Is There Scientific Support for This Model?
While the term “Secondary Akathisia” is not formally recognized in psychiatry, the mechanisms underlying the concept are well established across several domains of research.
Trauma psychology has long demonstrated that fear-conditioning and somatic memory can maintain physiological distress long after the original precipitating event has resolved. Interoceptive conditioning research shows that internal sensations can become powerful triggers when previously associated with threat.
Autonomic dysregulation is central to both post-traumatic stress and prolonged medication withdrawal syndromes.
Similarly, inhibitory learning models of exposure therapy demonstrate that avoidance maintains threat prediction, while gradual engagement allows the nervous system to update its expectations. In these frameworks, the goal is not to eliminate sensation, but to uncouple sensation from catastrophe.
Even clinical tools such as the Barnes Akathisia Rating Scale were developed primarily to assess acute, medication-induced presentations. They are less suited to evaluating longer-term, trauma-entrenched patterns where subjective distress may be driven by conditioned arousal rather than ongoing dopaminergic blockade.
In short, while the label “Secondary Akathisia” is conceptual rather than diagnostic, the processes it describes are grounded in established neuroscience: fear conditioning, autonomic sensitization, and learned threat amplification.
Treatment Considerations
Treatment depends heavily on mechanism. Interventions appropriate for acute, pharmacologically driven akathisia are different from those used when symptoms are maintained by conditioned autonomic activation.
For Primary Akathisia (Medication-Induced)
When akathisia is directly related to recent medication changes, management follows established psychiatric practice guidelines. The goal is to reduce dopaminergic imbalance and stabilize autonomic activation.
Common clinical interventions may include:
Dose reduction or medication adjustment, particularly in antipsychotic-induced cases
Beta-blockers (e.g., propranolol), which are among the most supported treatments in the literature
Short-term benzodiazepines, used cautiously and typically only in acute settings
Mirtazapine or cyproheptadine, which may modulate serotonergic involvement
Occasionally, adjunctive SSRIs, depending on presentation and comorbid features
Supportive body-based calming practices can be helpful, but primary akathisia often requires pharmacological stabilization when severe.
Importantly, for individuals already tapering benzodiazepines, medication additions must be approached with careful medical supervision. The goal is stabilization, not introducing additional volatility through a bunch of new medications or supplements into an already sensitized system.
For Persistent or Conditioned Presentations (Secondary Model)
When restlessness persists beyond the acute pharmacological window and appears driven by conditioned fear, interoceptive sensitivity, or trauma-based autonomic imprinting, the treatment focus shifts.
Here the work becomes regulatory and neuroplastic rather than primarily pharmacological.
Interventions may include:
Limbic system retraining, focused on decoupling sensation from threat and rebuilding inhibitory learning
Trauma-informed therapies (e.g., Somatic Experiencing, IFS, or other bottom-up approaches)
Intentional movement, such as paced walking in nature, replacing frantic pacing with regulated motion
Graduated exposure to stillness, allowing the nervous system to relearn safety without collapse
Grounding and interoceptive awareness practices, strengthening tolerance for internal sensation
Creative engagement (music, art, writing), which provides structured release of activation while reinforcing agency
Environmental safety cues, such as warmth, predictability, and co-regulation
The objective is not to eliminate pacing immediately or suppress activation forcefully. The objective is to retrain the nervous system so that stillness no longer signals danger.
In this model, symptoms are not viewed as permanent damage but as a nervous system stuck in learned alarm.
And learned alarm can be modified.
Again, this is where our Recovery Program can, and Recovery School can shine. Having a North Star, a grounded approach and roadmap to recovery, along with positive co-regulation, and learning to disengage from fear-fueling triggers, can absolutely be a game changer.
Does it go away?
Yes! As a recovery coach who has worked with thousands of people from across the globe, I can tell you that it always goes away. However, everyone is different, with different variables and circumstances. While rare, most akathisia symptoms seem to resolve within 1 to 3 months of onset. When they do occur, it’s usually in people who were on stronger doses of a benzo or antidepressant, for longer periods of time, and then cold-turkeyed or rapidly tapered.
However, that’s not always the case. In fact, that’s not even usually the case.
Akathisia is an outlier of a symptom that very few people truly experience. Many people confuse true akathisia with other withdrawal symptoms, such as adrenaline surges, restlessness, agitation, and the overall feeling of being sped up or the need to run, flee, or move. However, these are anxiety-related, and they will also gradually disappear.
However, people can indeed experience this terrible symptom for longer periods of time, but that is usually better associated with secondary akathisia, which is just as debilitating but tends to stick around for different reasons. Instead of direct receptor injury or dysregulation, secondary akathisia is more about the limbic system stuck in survival mode, which can be retrained over time and with work.
It has been my experience that it is extremely rare for someone to develop akathisia while doing a slow, gradual taper, or in individuals who came off their benzos after a shorter span of use. Still, this troubling symptom has become quite the boogieman in the benzo community.
I personally experienced it when I dropped 20mg of Valium overnight. I’d pace for hours, and even included this in my benzo recovery film, Lake of Fire. Robin, the protagonist, is seen pacing often in the first half of the film.
Please, do not let your Bear be consumed with this fear! Like all benzo withdrawal symptoms, it does go away, and it can be managed. Our recovery work is paramount and addresses so many of the things you’re worried about. Focus on your work. Befriend your Bear. Disengage from the fear-driven communities, and help your nervous system relearn safety.
You have the tools here in our school and in our program to do so. Do not fear the outcome, for a beautiful, symptom-free life awaits you on the other side, and you will reemerge a better version of yourself.
References
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Publishing.
Ashton, H. (2005). The diagnosis and management of benzodiazepine dependence. Current Opinion in Psychiatry, 18(3), 249–255.
Barnes, T. R. E. (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672–676.
Berridge, K. C., & Robinson, T. E. (1998). What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience? Brain Research Reviews, 28(3), 309–369.
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015). Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review. Psychotherapy and Psychosomatics, 84(2), 72–81
LeDoux, J. E. (2012). Rethinking the emotional brain. Neuron, 73(4), 653–676.
Miller, C. H., & Fleischhacker, W. W. (2000). Managing antipsychotic-induced acute and chronic akathisia. Drug Safety, 22(1), 73–81.
Phelps, E. A., Hofmann, S. G., & Lissek, S. (2018). Updating fear learning through exposure: Neural mechanisms and clinical implications. Neuropsychopharmacology, 43(1), 1–17.
Shipko, S. (2013). Serotonin reuptake inhibitors and withdrawal syndromes. Primary Psychiatry, 20(1), 47–52.
Vervliet, B., Craske, M. G., & Hermans, D. (2013). Fear extinction and relapse: State of the art. Annual Review of Clinical Psychology, 9, 215–248.
World Health Organization. (2020). The ICD-11 classification of mental and behavioural disorders. WHO.